Applying the same analysis to stage II breast cancer patients revealed that the CINP metagene was associated with a marginally significant difference in 5-year survival by TCGA analysis but not by METABRIC analysis (Supplementary Fig. 4b, c). This evidence concerns the gene CINP and breast carcinoma.